AGC Si-Tech Co.,Ltd. provides
unique silica products and material solutions
for customer's various demands.

Topics

10th September 2021
A COVID-19 infected person has occurred.

We would like to inform you that one employee working at our head office underwent a COVID test on September 6, 2021 and was found to be positive.
The last working day before the infection was identified was September 5th, the employee is currently recuperating at a hotel.
There is no impact to our production activities or product shipments.
We have been thoroughly preventing infections by recommending working at home, encouraging staggered commuting, washing hands and wearing masks.
Going forward, we will continue to give top priority to the health and safety of our customers, business partners, and employees, and make effort to prevent the spread of infection inside and outside the company.

Contact in this regards: AGC Si-Tech Co., Ltd. Administration Office
‘+81-93-761-1136
27th August 2021
A COVID-19 infected person has occurred.

We would like to inform you that one employee working at our head office underwent a COVID test on August 18, 2021 and was found to be positive.
The last working day before the infection was identified was August 16th, the employee is currently being treated at home.
There is no impact to our production activities or product shipments.
We have been thoroughly preventing infections by recommending working at home, encouraging staggered commuting, washing hands and wearing masks.
Going forward, we will continue to give top priority to the health and safety of our customers, business partners, and employees, and make effort to prevent the spread of infection inside and outside the company.

Contact in this regards: AGC Si-Tech Co., Ltd. Administration Office
‘+81-93-761-1136
4th June 2021
Notice regarding an agreement on collaboration with Sweden’s Sigrid Therapeutics

Sigrid Therapeutics and AGC Si-Tech ltd. have entered a collaboration with regards to a special tailor-made SiO2 product
supply for Sigrid’s lead product SiPore15®. SiPore15® an orally administered product,ingested with food to reduce
the uptake of carbohydrate and fats, designed to act locally in the gut.This unique fat/carbohydrate uptake reducing product will be
targeting a $22 billion prediabetes/obesity market working to reduce blood sugar levels in people at risk of developing type 2 diabetes.